Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics to Present at Upcoming Investor Conferences
NEW YORK , Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, is scheduled to participate in fireside chats during
Sep 09, 2020
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and
Aug 13, 2020
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
NEW YORK , Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “We are
Aug 10, 2020
TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Update
Investor Conference Call to be held Monday, August 10, 2020 at 8:30 AM ET NEW YORK , Aug. 06, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020
Aug 06, 2020
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
NEW YORK , July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the Company’s investigational oral once-daily dual inhibitor of PI3K-delta and CK1-epsilon, in Blood
Jul 08, 2020
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
NEW YORK , June 22, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual meeting, being held virtually. Michael S.
Jun 22, 2020
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
NEW YORK , June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S.
Jun 17, 2020
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET NEW YORK , June 16, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the Raymond James 2020 Human
Jun 16, 2020
TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress
NEW YORK , June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25 th   European Hematology Association (EHA) annual congress including data from a Phase 1 study evaluating TG-1701, the Company’s once daily, selective, BTK inhibitor, as
Jun 12, 2020
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET NEW YORK , June 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the
Jun 09, 2020
Displaying 1 - 10 of 28